The Activity of Trabectedin As a Single Agent or in Combination with Everolimus for Clear Cell Carcinoma of the Ovary

MLA

Takeshi Hisamatsu, et al. “The Activity of Trabectedin As a Single Agent or in Combination with Everolimus for Clear Cell Carcinoma of the Ovary.” Clinical Cancer Research, vol. 17, July 2011, pp. 4462–73. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....600001e7576a9bd375e1e1ba291827a2&authtype=sso&custid=ns315887.

APA

Takeshi Hisamatsu, Chiaki Kawase, Toshifumi Takahashi, Kenjirou Sawada, Kazuya Mimura, Hirohisa Kurachi, Kazuhiro Takahashi, Tadashi Kimura, Masami Hayashi, & Seiji Mabuchi. (2011). The Activity of Trabectedin As a Single Agent or in Combination with Everolimus for Clear Cell Carcinoma of the Ovary. Clinical Cancer Research, 17, 4462–4473.

Chicago

Takeshi Hisamatsu, Chiaki Kawase, Toshifumi Takahashi, Kenjirou Sawada, Kazuya Mimura, Hirohisa Kurachi, Kazuhiro Takahashi, Tadashi Kimura, Masami Hayashi, and Seiji Mabuchi. 2011. “The Activity of Trabectedin As a Single Agent or in Combination with Everolimus for Clear Cell Carcinoma of the Ovary.” Clinical Cancer Research 17 (July): 4462–73. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....600001e7576a9bd375e1e1ba291827a2&authtype=sso&custid=ns315887.